IXC Stock Overview
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Invex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.082 |
| 52 Week High | AU$0.63 |
| 52 Week Low | AU$0.06 |
| Beta | 0.43 |
| 1 Month Change | -3.53% |
| 3 Month Change | 1.23% |
| 1 Year Change | -82.37% |
| 3 Year Change | -88.84% |
| 5 Year Change | n/a |
| Change since IPO | -92.37% |
Recent News & Updates
Recent updates
We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Jun 09
We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Jan 11We Think Invex Therapeutics (ASX:IXC) Can Afford To Drive Business Growth
Aug 24Companies Like Invex Therapeutics (ASX:IXC) Are In A Position To Invest In Growth
May 10Companies Like Invex Therapeutics (ASX:IXC) Can Afford To Invest In Growth
Jan 25We're Interested To See How Invex Therapeutics (ASX:IXC) Uses Its Cash Hoard To Grow
Sep 27We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Mar 31Should You Review Recent Insider Transactions At Invex Therapeutics Ltd (ASX:IXC)?
Feb 06We're Hopeful That Invex Therapeutics (ASX:IXC) Will Use Its Cash Wisely
Dec 15
Shareholder Returns
| IXC | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -3.5% | -2.6% | 0.9% |
| 1Y | -82.4% | 29.2% | 5.7% |
Return vs Industry: IXC underperformed the Australian Pharmaceuticals industry which returned 31.3% over the past year.
Return vs Market: IXC underperformed the Australian Market which returned 5.6% over the past year.
Price Volatility
| IXC volatility | |
|---|---|
| IXC Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 10.7% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IXC has not had significant price volatility in the past 3 months.
Volatility Over Time: IXC's weekly volatility has decreased from 18% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | n/a | www.invextherapeutics.com |
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.
Invex Therapeutics Ltd Fundamentals Summary
| IXC fundamental statistics | |
|---|---|
| Market cap | AU$6.16m |
| Earnings (TTM) | -AU$6.01m |
| Revenue (TTM) | AU$12.18k |
506.2x
P/S Ratio-1.0x
P/E RatioIs IXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXC income statement (TTM) | |
|---|---|
| Revenue | AU$12.18k |
| Cost of Revenue | -AU$300.41k |
| Gross Profit | AU$312.59k |
| Other Expenses | AU$6.33m |
| Earnings | -AU$6.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.08 |
| Gross Margin | 2,567.45% |
| Net Profit Margin | -49,400.20% |
| Debt/Equity Ratio | 0% |
How did IXC perform over the long term?
See historical performance and comparison